<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193622</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI UNKPRI 15</org_study_id>
    <secondary_id>AVF 2968s</secondary_id>
    <nct_id>NCT00193622</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site</brief_title>
  <official_title>A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <brief_summary>
    <textblock>
      This trial will investigate the combination of bevacizumab, and erlotinib in patients with&#xD;
      adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and&#xD;
      erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This&#xD;
      trial will be one of the first clinical trials to evaluate a combination of targeted agents&#xD;
      in the treatment of a solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, patients will be receive:&#xD;
&#xD;
        -  Bevacizumab + Erlotinib&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Neoplasms, Unknown Primary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in this study, you must meet the following criteria:&#xD;
&#xD;
          -  Carcinoma of unknown primary site confirmed by biopsy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  ECOG performance status must be 0-1&#xD;
&#xD;
          -  Adequate bone marrow, liver and kidney&#xD;
&#xD;
          -  Understand the nature of this study and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        You cannot participate in this study if any of the following apply to you:&#xD;
&#xD;
          -  Age&lt; 18 years&#xD;
&#xD;
          -  May not have received EGFR inhibitors&#xD;
&#xD;
          -  History of acute myocardial infarction within 6 months&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Moderate to severe peripheral vascular disease.&#xD;
&#xD;
          -  History of stroke within 6 months&#xD;
&#xD;
          -  History of abdominal fistula, perforation, or abscess within 6 months&#xD;
&#xD;
          -  Active concurrent infections&#xD;
&#xD;
          -  Serious underlying medical conditions&#xD;
&#xD;
          -  Active brain metastases&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  PEG or G-tube&#xD;
&#xD;
          -  Proteinuria&#xD;
&#xD;
          -  Any nonhealing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Any clinical evidence or history of bleeding, clotting or coagulopathy&#xD;
&#xD;
        Please note: There are additional inclusion/exclusion criteria. The study center will&#xD;
        determine if you meet all of the criteria. If you do not qualify for the trial, study&#xD;
        personnel will explain the reasons. If you do qualify, study personnel will explain the&#xD;
        trial in detail and answer any questions you may have.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Hainsworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <link>
    <url>http://jco.ascopubs.org/cgi/content/full/25/13/1747</url>
    <description>Published article in the Journal of Clinical Oncology</description>
  </link>
  <results_reference>
    <citation>Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007 May 1;25(13):1747-52.</citation>
    <PMID>17470864</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

